AstraZeneca Unburdens Itself Of Brodalumab
This article was originally published in Scrip
Executive Summary
AstraZeneca plc has managed to offload the dermatology candidate brodalumab to Valeant Pharmaceuticals International Inc following Amgen's decision to pull out of a co-development deal earlier this year. Amgen made the move owing to potential side effect issues, with suicidal thoughts being linked to brodalumab administration during clinical development, despite evidence of efficacy.
You may also be interested in...
Key Clinical Data And Drug Approvals Expected In 2H 2016
As July is already upon us, Scrip takes a look at some of the more interesting clinical trial read-outs and drug approvals expected clinical trials due to report in the second half of the year.
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry
Agency's advisors were divided on whether Valeant's proposal for voluntary registry would suffice or whether mandatory program under REMS was needed to better assess risk of suicide and suicidal behavior with psoriasis drug.
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Program may provide drugs with narrower labels an opportunity to gain preferred formulary status versus entrenched market leaders.